@article{195d96199ecb4c5dad26722a1acc6525,
title = "Optimizing the use of the hyperCVAD regimen: Clinical vignettes and practical management",
keywords = "acute lymphoblastic leukemia, blinatumomab, hyperCVAD, hyperfractionated cyclophosphamide, inotuzumab, safety",
author = "Rausch, {Caitlin R.} and Jabbour, {Elias J.} and Kantarjian, {Hagop M.} and Kadia, {Tapan M.}",
note = "Funding Information: Elias J. Jabbour has received research grants and personal fees from Abbvie, Adaptive Biotechnologies, Amgen, Bristol‐Myers Squibb, Pfizer, and Takeda. Hagop M. Kantarjian has received research grants from Abbvie, Agios, Amgen, Ariad, Astex, Bristol‐Myers Squibb, Cyclacel, Daiichi‐Sankyo, Immunogen, Jazz Pharma, Novartis, and Pfizer and personal fees from AbbVie, Actinium, Agios, Amgen, Pfizer, and Takeda. Tapan M. Kadia has received research funding from Amgen, Bristol‐Myers Squibb, and Pfizer and personal fees from Amgen and Novartis. The other authors made no disclosures. ",
year = "2020",
month = mar,
day = "15",
doi = "10.1002/cncr.32606",
language = "English (US)",
volume = "126",
pages = "1152--1160",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "6",
}